Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT07815431
Starting soon Observational

MC1R Mutations Associated With Red Hair and Perioperative Anesthesia Complications

NCT07815431 · tracked via the Priya Life Science Sweden tracker
Sponsor
Uppsala University
Phase
Observational
Started
2026-09
Last updated
2026-09-11

Condition(s) studied

Anaesthesia ComplicationPerioperative Adverse EventsRed HairMelanocortin 1 Receptor

Study summary

The study aims to investigate whether patients with Melanocortin-1 receptor (MC1R) mutations, associated with red hair, or having a red hair phenotype, have a higher incidence of anesthesia-related perioperative complications. Genomic data from patients that have undergone a surgical or medical procedure, requiring an anesthetic management are extracted from two cohorts - a Swedish (Merged Anaesthesia and Intensive Care Cohort in Sweden (MAICS)), and a British (UK Biobank UKBB)), and linked to relevant healthcare registries. The outcome variables studied are statistically adjusted for age, gender, timing of procedure during the study period, and socioeconomic factors.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * A qualifying surgical procedure requiring specified anesthetic management. * A qualifying medical procedure requiring specified anesthetic management. * Caucasian origin. Exclusion Criteria: * None specified.

Primary outcome measure(s)

  • Serious adverse events occurring after a surgical, or medical procedure requiring anesthetic. — Days 30 after a qualifying procedure.
    A composite of adverse events consisting of Death, Unplanned ICU-admission, Myocardial arrest (ICD10: I46), Myocardial infarction (ICD10: I21-22), Pneumonia (ICD10: J13-16, J18, J85, J86, A481), and Anaphylaxis (ICD10: T782, T805, T886) Up until 30 days after the procedure.

Trial sites (1)

FacilityCityRegionStatus
Uppsala University, Department of Surgical Sciences Uppsala Sweden

More Uppsala University trials in Sweden

Efficacy of Hyperthermic Intraperitoneal Chemotherapy Recruiting
Robotic-Assisted Pedicle Screw Placement in Spine Surgery Recruiting
The Scandinavian Displaced Lateral Clavicle Trial Recruiting
Fusion or Not - a Study on Low Back Pain Recruiting
Nutrition and Inflammation in Patients With Head and Neck Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07815431 on ClinicalTrials.gov ↗ ← All trials in Sweden